Case 2: KIT Exon 9-Mutated GIST
The experts present and discuss a case of a patient with KIT exon 9-mutated GIST, an including an overview of surgical options.
Case 1: INVICTUS Trial
The panelists discuss the phase 3 INVICTUS trial of ripretinib and the phase 1 study of ripretinib intra-patient dose escalation.
Case 1: Treatment Considerations in GIST
Third-line treatment recommendations for patients with GIST and a discussion on side effect management.
Case 1: Molecular Testing in GIST
Experts discuss the considerations of lines of therapy, comment on molecular testing, and the role of repeat biopsies.
Case 1: 66-Year-Old Woman With GIST
The experts discuss a case presentation of a 66-year-old woman with heavily pretreated GIST, and comment on follow-up times and treatment options.
Clinical Cases in Gastrointestinal Stromal Tumors
Experts review 3 clinical cases, discuss treatment options and relevant clinical trials in GIST.
Advice on Future Treatment of HCC
Ruth He, MD, grants advice on how to treat patients with unresectable hepatocellular carcinoma.
Emerging Combination Therapies for HCC
Ruth He, MD, discusses potential options for physicians in their treatment of unresectable hepatocellular carcinoma.
Unmet Needs of HCC Management
Ruth He, MD, acknowledges the current struggles experts face in combatting unresectable hepatocellular carcinoma.
Approval of Frontline Atezolizumab + Bevacizumab Treatment
Ruth He, MD, discusses the approval of frontline atezolizumab-bevacizumab and its relation to subsequent treatment of patients with unresectable hepatocellular carcinoma.
Atezolizumab and Bevacizumab in the Phase 3 IMbrave150 Trial
Ruth He, MD, discusses major takeaways from the phase 3 IMbrave150 trial of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma.
Frontline Systemic Therapy in HCC Patients
Ruth He, MD, highlights factors that influence her use of frontline systemic therapy in patients with unresectable hepatocellular carcinoma.
ASCO GI 2021 OS Update: IMbrave150
Ruth He, MD, discusses the current treatment options for unresectable hepatocellular carcinoma.
SABCS 2020 Wrap-Up
Final analysis of data on HER2-positive disease presented at the 2020 San Antonio Breast Cancer Symposium from experts in the field of breast oncology.
Promising Data for Trastuzumab Deruxtecan Combination
Experts in breast oncology discuss the evolving role of trastuzumab deruxtecan for metastatic HER2-positive breast cancer.
SABCS 2020: PERTAIN Updates in HER2+, HR+ MBC
Hatem Soliman, MD, reviews statistically significant data from the PERTAIN study, presented at the 2020 San Antonio Breast Cancer Symposium.
Ongoing Role of TDM-1 in Metastatic Breast Cancer
Experts in breast oncology discuss their real-world experience with trastuzumab emtansine (T-DM1) for patients with advanced HER2-positive breast cancer.
Disease-Free Interval and Overall Survival in HER2+ BC
Analysis from the ALTTO (BIG 2-06) trial and the relationship between a short or long disease-free interval and overall survival.
De-escalation in Neoadjuvant Setting for HER2+ BC
Updated findings on the use of neratinib for HER2+ breast cancer from the 2020 SABCS Virtual Symposium.
SABCS 2020 Updates: ExteNET and CONTROL Trials
Prognostic Tools for Early Stage BC
A discussion on the importance of prognostic tools for early stage breast cancer.
Predictive Biomarkers: HER2-Enriched Subtypes
Hatem Soliman, MD, discusses data presented at the 2020 SABCS for patients with HER2-enriched subtypes that showed benefit from CDK4/6 inhibition.
HER2+ BC: Unanswered Questions in Sequencing
Andrew Seidman, MD, provides insight on clinical sequencing for patients with advanced HER2-positive breast cancer.
2020 in Review: HER2+ Breast Cancer
Experts in breast oncology discuss the evolving landscape in early stage and metastatic HER2-positive breast cancer.
Future Treatment Landscape of RAI-Refractory DTC
Steven Sherman, MD, FACE, provides closing thoughts on unmet needs and future directions for the treatment of patients with RAI-refractory DTC.
RAI-Refractory DTC: Patient Education of Systemic Therapy
Approaching patient education of RAI-refractory DTC therapy with lenvatinib, fostering open communication between patients and providers, and monitoring medication adherence.
Managing Adverse Events in RAI-Refractory DTC Therapy
An expert endocrinologist perspective on managing the toxicities associated with lenvatinib when treating RAI-refractory DTC and the role of dose reduction and interruption.
Dosing of TKI Therapy for RAI-Refractory DTC
A review of a multicenter phase 2 study evaluating the safety and efficacy of lenvatinib starting doses in RAI-refractory DTC.
Phase 3 SELECT Trial
A review of the phase 3 SELECT trial examining the use of lenvatinib for the treatment of RAI-refractory DTC and the management of adverse events.
Overview of RAI-Refractory DTC
Steven Sherman, MD, FACE, provides an overview of the history and evolution of treating patients with RAI [radioactive iodine]–refractory differentiated thyroid cancer [DTC].